Molecular Templates Inc (MTEM)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Molecular Templates Inc chart...

About the Company

molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.

CEO

Eric Poma

Exchange

NASDAQ

Website

https://mtem.com/

$0M

Total Revenue

205

Employees

$15M

Market Capitalization

-1.55

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MTEM News

MTEM Molecular Templates, Inc.

4d ago, source: Seeking Alpha

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in ...

Molecular Templates, Inc. Provides Interim Update

14d ago, source: Business Insider

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage ...

Stocks to Watch: Brand Engagement Network, Molecular Templates

3d ago, source:

By Sabela Ojea Brand Engagement Network went public through a special-purpose acquisition company merger. Shares of the provider of personalized ...

Molecular Templates, Inc. (NZW.F)

27d ago, source: Yahoo Finance

Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the ...

Molecular Templates, Inc. Provides Interim Update

15d ago, source: Yahoo Finance

MT-8421 Induces Unique Pharmacodynamic Effects AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates ...

Molecular Templates Inc MTEM

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Molecular Templates, Inc. Provides Interim Update

14d ago, source: Stockhouse

Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study AUSTIN, Texas, March 04, 2024 (GLOBE ...

Molecular Templates, Inc. Provides Interim Update

15d ago, source: ADVFN

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted ...

Molecular Templates, Inc. Provides Interim Update

14d ago, source: Finanznachrichten

Molecular Templates, Inc.: Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference 17.01. Molecular Templates, Inc. - 8-K, Current Report ...

Molecular Templates, Inc. Provides Interim Update

14d ago, source: Yahoo Finance

MT-8421 Induces Unique Pharmacodynamic Effects AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...